Mitoxantrone-d8 (dihydrochloride)

• UNSPSC Description:

  Mitoxantrone-d8 dihydrochloride is deuterated labeled Mitoxantrone dihydrochloride (HY-13502A). Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity[1][2][3][4]. Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively[5].

• Target Antigen:

  Apoptosis; Endogenous Metabolite; Isotope-Labeled Compounds; Orthopoxvirus; PKC; Topoisomerase

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Apoptosis;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease;Others;TGF-beta/Smad

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cancer; Infection

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=C(C(NCCNC([2H])([2H])C([2H])([2H])O)=CC=C2NCCNC([2H])([2H])C([2H])([2H])O)C(C3=C(O)C=CC(O)=C13)=O.[H]Cl.[H]Cl

• Molecular Weight:

  525.45

• References & Citations:

  [1]Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7.|[2]Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. |[3]Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.|[4]Venza I, et al. Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res. 2013 Mar;26(2):193-204.|[5]Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported